Evidence map›Paper›PMID 42428810›Full record

ArticleAPL bioengineering2026

Structural and functional benchmarking of monolayer- and bioreactor-generated hiPSC-derived cardiomyocytes.

Yongjun Jang, Kevin Shani, Anna Clouvel-Gervaiseau, Maksymilian Prondzynski, Simone Nuebling, Christopher J Shin, Yichong Wang, Giulio Ciucci, Michio Kawai, Yoonseo Lee and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in APL bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yongjun JangORCID https://orcid.org/0000-0002-0508-4341
Kevin ShaniORCID https://orcid.org/0009-0006-6263-9784
Anna Clouvel-GervaiseauDisease Biophysics Group, John A. Paulson School of Engineering and Applied Sciences, Harvard University, Boston, Massachusetts 02134, USA.ORCID https://orcid.org/0009-0008-7380-5666
Maksymilian ProndzynskiORCID https://orcid.org/0000-0002-6846-6435
Simone NueblingDisease Biophysics Group, John A. Paulson School of Engineering and Applied Sciences, Harvard University, Boston, Massachusetts 02134, USA.ORCID https://orcid.org/0009-0003-2147-2349
Christopher J ShinDepartment of Cardiology, Boston Children's Hospital, Boston, Massachusetts 02115, USA.ORCID https://orcid.org/0009-0007-5042-1275
Yichong WangDisease Biophysics Group, John A. Paulson School of Engineering and Applied Sciences, Harvard University, Boston, Massachusetts 02134, USA.ORCID https://orcid.org/0009-0008-2407-0288
Giulio CiucciDisease Biophysics Group, John A. Paulson School of Engineering and Applied Sciences, Harvard University, Boston, Massachusetts 02134, USA.ORCID https://orcid.org/0009-0000-0344-2718
Michio KawaiDisease Biophysics Group, John A. Paulson School of Engineering and Applied Sciences, Harvard University, Boston, Massachusetts 02134, USA.ORCID https://orcid.org/0009-0004-8569-0422
Yoonseo LeeDisease Biophysics Group, John A. Paulson School of Engineering and Applied Sciences, Harvard University, Boston, Massachusetts 02134, USA.ORCID https://orcid.org/0000-0002-6404-2539
Griffin RadtkeDisease Biophysics Group, John A. Paulson School of Engineering and Applied Sciences, Harvard University, Boston, Massachusetts 02134, USA.ORCID https://orcid.org/0000-0001-9841-396X
Durgesh BondeDepartment of Cardiology, Boston Children's Hospital, Boston, Massachusetts 02115, USA.ORCID https://orcid.org/0000-0002-5630-0438
William T PuORCID https://orcid.org/0000-0002-4551-8079
Kevin Kit ParkerORCID https://orcid.org/0000-0002-5968-7535

Funding

Desmosomes in cardiomyocyte homeostasis and diseaseR01HL167450 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI William Tswenching Pu · 2023 to 2026
$3.1M
Tissue chips for precision treatment of catecholaminergic polymorphic ventricular tachycardia - Diversity Supplement for Nnaemeka Justin AnyanwuUH3TR003279 · NCATS · BOSTON CHILDREN'S HOSPITAL · PI PARKER, KEVIN KIT, PU, WILLIAM TSWENCHING · 2022 to 2024
$2.5M
NCATS NIH HHS UH3 TR003279NHLBI NIH HHS R01 HL167450
6 · The paper itself

Abstract

Transitioning from animal to human cell sources represents a critical milestone in cardiac tissue engineering and biomedical research. Neonatal rat ventricular myocytes (NRVMs) have long served as the functional benchmark for engineered cardiac tissues; however, their rodent origin limits clinical relevance. Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offer a renewable, species-specific alternative but remain restricted by immature structure and function, small-scale yield, and high batch variability by conventional two-dimensional monolayer (2D-Mono) differentiation. Here, we systematically evaluated hiPSC-CMs generated by 2D-Mono and three-dimensional embryoid-body (3D-EB) differentiation using identical 15-day Wnt-modulated protocols without additional maturation steps. The 3D-EB method yielded 181 × 10

Identifiers

PMID42428810
PMCPMC13349655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.